Dual-Targeted Radionuclide Therapy with 161Tb Instigates Anticancer Immunity in "Cold" Murine Prostate Tumor.

It is noted, however, that 177Lu with moderate radiation energy achieves effective tumor inhibition at a relatively high dose and has a low capacity to activate "cold" prostate tumor.

In this study, we report that Sigma-1 receptor and prostate-specific membrane antigen (prostate-specific membrane antigen) dual-targeted peptide (S1R/prostate-specific membrane antigen-P) labeled with 161Tb, which emits locally high linear energy transfer (linear energy transfer) Auger electrons, effectively inhibits prostate tumor and energizes anticancer immunity.